Jazz Pharmaceuticals, Inc. under Investor Investigation over possible Violations of Securities Laws

Oct. 26, 2011 - PRLog -- An investigation on behalf of investors in shares of Jazz Pharmaceuticals, Inc.  over possible Violations of Federal Securities Laws was announced.

If you purchased shares of Jazz Pharmaceuticals, Inc. , and / or if you have any information relating the investigation including those who are former employees or/and whistleblowers, you may have certain options and you should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Jazz Pharmaceuticals, Inc.  concerning whether the company, certain of its officers and directors, or others have possibly violated federal securities laws. Specifically, the investigation concerns whether certain statements regarding Jazz Pharmaceuticals’ business, its prospects and its operations were potentially materially false and misleading at the time they were made.

Jazz Pharmaceuticals’ has reported an increasing financial performance in the past years. Jazz Pharmaceuticals reported that its annual Revenue rose from $65.30million in 2007 to $173.78million in 2010 and that its Net Income increased from a Net Loss of $138.83million in 07, respectively $184.34million in 08, to a Net Income of $32.78million in 2010. For the second quarter 2011 Jazz Pharmaceuticals reported that its second quarter Revenue rose from $40.49million last year to $64.57million this year and that its second quarter Net Income grew from a second quarter 2010 Net Loss of $6.39million to a second quarter 2011 Net Income of $33.20million.

Shares of Jazz Pharmaceuticals, Inc. (Public, NASDAQ-JAZZ) grew from as low as $0.83 per share in May 2009 to as high as $44.14 per share in October 2011.

On October 18, 2011, media outlets reported the Jazz Pharmaceuticals, Inc received warning letter dated Oct 11, 2011, from the Food and Drug Administration (“FDA”). The Wall Street Journal for instance said that drug companies are required to report to FDA any reports of side-effects that might be associated with drugs sold by the company.

The warning letter reportedly cited Jazz Pharmaceuticals for failing to report 74 reports of serious drug side effects or injuries within 15 calendar days of initial receipt between the time period of January 2003 through December 2010.  FDA inspectors reportedly said Jazz Pharmaceuticals had allegedly failed to develop written procedures for monitoring and submitting adverse reports to the FDA
Shares of Jazz Pharmaceuticals fell from over $45 per share on October 12, 2011 to as low as $37.06 on October 20, 2011.

Those who purchased shares of Jazz Pharmaceuticals, Inc. (Public, NASDAQ-JAZZ), and / or those who have any information relating the investigation including those who are former employees or/and whistleblowers, may have certain options and you should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

# # #

The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group. We do research related to shareholder issues and inform investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. At Shareholders Foundation, Inc. we are in contact with a large number of shareholders. We offer help, support, and assistance for every shareholder. We help investors find answers to their questions and equitable solutions to their problems. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.